An insider shareholder named Barchas sold 211,763 [1] residual shares of Immunome just before the U.S. Food and Drug Administration accepted a New Drug Application.

The timing of the sale is significant because it occurred the day before the FDA accepted the application for varegacestat, a drug intended to treat desmoid tumors [2]. While insider sales can sometimes signal a lack of confidence in a company, this specific transaction was executed under a Rule 10b5-1 trading plan [1].

Rule 10b5-1 plans allow company insiders to set up a predetermined schedule for selling stocks to avoid accusations of insider trading. According to available records, Barchas adopted this specific trading plan in March 2026 [1]. By establishing the sale parameters months in advance, the insider aimed to execute the trade regardless of any pending regulatory news.

The FDA's acceptance of the New Drug Application represents a critical regulatory milestone for Immunome [2]. This step moves varegacestat closer to potential market approval, as the agency begins its formal review of the drug's safety and efficacy.

Because the sale was automated via the March 2026 [1] plan, the transaction was not a discretionary move made in response to the immediate FDA milestone. The sale of 211,763 [1] shares reflects the execution of a long-standing financial strategy rather than a reaction to the current regulatory timeline.

“Barchas sold 211,763 residual shares of Immunome”

The use of a Rule 10b5-1 plan provides a legal shield for insiders, demonstrating that the sale was scheduled independently of the FDA's acceptance of the varegacestat application. For investors, the key takeaway is that the insider's divestment does not necessarily indicate a negative outlook on the drug's prospects, as the trade was locked in months before the regulatory milestone was reached.